Your browser doesn't support javascript.
loading
Portable air-fed cold atmospheric plasma device for postsurgical cancer treatment.
Chen, Guojun; Chen, Zhitong; Wang, Zejun; Obenchain, Richard; Wen, Di; Li, Hongjun; Wirz, Richard E; Gu, Zhen.
Afiliação
  • Chen G; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  • Chen Z; California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  • Wang Z; Department of Biomedical Engineering and the Rosalind & Morris Goodman Cancer Research Centre, McGill University, Montreal, QC H3A 1A3, Canada.
  • Obenchain R; Department of Mechanical and Aerospace Engineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  • Wen D; National Innovation Center for Advanced Medical Devices, Shenzhen 518000, China.
  • Li H; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  • Wirz RE; California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  • Gu Z; Department of Mechanical and Aerospace Engineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Sci Adv ; 7(36): eabg5686, 2021 Sep 03.
Article em En | MEDLINE | ID: mdl-34516919
ABSTRACT
Surgery represents the major option for treating most solid tumors. Despite continuous improvements in surgical techniques, cancer recurrence after surgical resection remains the most common cause of treatment failure. Here, we report cold atmospheric plasma (CAP)­mediated postsurgical cancer treatment, using a portable air-fed CAP (aCAP) device. The aCAP device we developed uses the local ambient air as the source gas to generate cold plasma discharge with only joule energy level electrical input, thus providing a device that is simple and highly tunable for a wide range of biomedical applications. We demonstrate that local aCAP treatment on residual tumor cells at the surgical cavities effectively induces cancer immunogenic cell death in situ and evokes strong T cell­mediated immune responses to combat the residual tumor cells. In both 4T1 breast tumor and B16F10 melanoma models, aCAP treatment after incomplete tumor resection contributes to inhibiting tumor growth and prolonging survival.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Sci Adv Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Sci Adv Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos